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It has previously been shown that, in the heterozygous
state, mutations in the SOX9 gene cause campomelic
dysplasia (CD) and the often associated autosomal XY
sex reversal. In 12 CD patients, 10 novel mutations and
one recurrent mutation were characterized in one
SOX9 allele each, and in one case, no mutation was
found. Four missense mutations are all located within
the high mobility group (HMG) domain. They either re-
duce or abolish the DNA-binding ability of the mutant
SOX9 proteins. Among the five nonsense and three
frameshift mutations identified, two leave the C-terminal
transactivation (TA) domain encompassing residues
402–509 of SOX9 partly or almost completely intact.
When tested in cell transfection experiments, the recur-
rent nonsense mutation Y440X, found in two patients
who survived for four and more than 9 years, respect-
ively, exhibits some residual transactivation ability. In
contrast, a frameshift mutation extending the protein by
70 residues at codon 507, found in a patient who died
shortly after birth, showed no transactivation. This is
apparently due to instability of the mutant SOX9 protein
as demonstrated by Western blotting. Amino acid sub-
stitutions and nonsense mutations are found in patients
with and without XY sex reversal, indicating that sex re-
versal in CD is subject to variable penetrance. Finally,
none of 18 female patients with XY gonadal dysgenesis
(Swyer syndrome) showed an altered SOX9 banding
pattern in SSCP assays, providing evidence that SOX9
mutations do not usually result in XY sex reversal with-
out skeletal malformations.
INTRODUCTION
Campomelic dysplasia (CD) is a rare, often lethal, dominantly
inherited, congenital osteochondrodysplasia, associated with
male-to-female autosomal sex reversal in two-thirds of the
affected karyotypic males. Prominent features of CD are bowing
of femora and tibiae, hypoplastic scapulae, 11 instead of 12 pairs
of ribs, Robin sequence, pelvic malformations and bilateral
clubfeet. The majority of CD patients die neonatally due to
respiratory distress (1,2). By positional cloning in combination
with positional candidate information, the SOX9 gene on
chromosome 17q was isolated from the vicinity of breakpoints in
CD patients with reciprocal de novo translocations (3,4). Proof of
SOX9 being responsible for both CD and XY sex reversal came
from the demonstration of de novo heterozygous loss-of-function
mutations within the SOX9 coding region in non-translocation
CD patients (3–5). Unexpected and still unexplained remains the
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observation that the breakpoints in all six translocation patients
studied do not interrupt the SOX9 gene but map 50 kb or more 5′
to the gene (3,4,6,7). In line with the generalized defect in skeletal
development seen in CD patients, the mouse Sox9 gene has been
shown to be expressed in mesenchymal condensations before and
during embryonic cartilage deposition, consistent with a primary
role for SOX9/Sox9 in skeletal formation (8).
Like the Y-located testis-determining gene SRY, SOX9 is a
member of the SOX gene family of transcription factors. SOX
proteins share an amino acid sequence identity of 60% or more
in their high-mobility group (HMG) domain with the HMG
domain present in SRY (9). The HMG domain is an 80 amino acid
DNA-binding and bending motif that characterizes, besides the
SOX proteins, a whole class of transcription factors (10). Apart
from the HMG domain, the 509 residue SOX9 protein contains
two additional protein motifs: first, a stretch of 41 residues
(residues 339–379) composed solely of proline, glutamine and
alanine (PQA motif), the function of which is unknown; secondly,
a C-terminal transcription activation domain rich in serine,
proline and glutamine, ranging from residues 402–509 (11).
Up to now, a total of 13 SOX9 mutations have been published
(3–5). As these mutations are all heterozygous and appear to cause
loss of function of SOX9, CD can be regarded as a haploinsuffi-
ciency syndrome. To gain more insight into the mutational
spectrum in CD and to see whether or not some genotype/pheno-
type correlations emerge regarding XY sex reversal, survival or
severity of disease, we have extended our previous study to 12 new
CD cases with and without XY sex reversal. We have thus
identified 10 novel SOX9 mutations and one recurrent mutation,
and have analysed some of these mutations in functional assays. In
addition, we have screened DNA samples from patients with XY
gonadal dysgenesis (Swyer syndrome) known to have an intact
SRY gene for mutations in SOX9.
RESULTS
Novel and recurrent SOX9 mutations detected in 12
CD patients
We have screened PCR-derived fragments spanning the complete
coding region, the four exon/intron boundaries, and 133 bp from the
promoter region of the three-exon SOX9 gene in DNA from 12
unrelated patients for mutations. Three cases have been screened by
the single strand conformation polymorphism (SSCP) assay (12),
with two showing an altered banding pattern due to a pathologically
relevant mutation as shown by DNA sequence analysis of the
relevant PCR product. The third case and the remaining nine cases
have been analysed by direct sequencing of PCR products. The
karyotypes and sexual phenotypes of the patients studied are listed
in Table 1, in addition to the specific mutations detected in all but
one of the cases. These mutations, which are all in the heterozygous
state, will here be presented in detail.
A W86X (TGG→TAG) nonsense mutation was identified
proximal to the HMG box in patient M.R., removing all
functional domains of SOX9. A sister of this patient also died
from CD shortly after birth. Whereas DNA from this sister was
unavailable, leukocyte DNA from a healthy sister, from both
parents as well as amniocyte DNA from an actual pregnancy
proved negative for the W86X mutation. Germ-line mosaicism in
one of the parents is the likely cause for the recurrence of CD in
this family. Another nonsense mutation, Q117X (CAG→TAG),
was identified in patient J.N., who survived for 12 years. This
mutation occurs in the first third of the HMG box, leading to a
truncated protein lacking 393 of 509 amino acid (aa) residues.
Therefore, the resulting protein should be deficient in most, if not
all, of its functional domains. DNA of both parents proved
negative for the mutation.
Missense mutations resulting in reduction or loss of DNA
binding of the mutant SOX9 protein (see below) were detected in
four patients. A P108L (CCC→CTC) and a W143R
(TGG→CGG) mutation were found in patients A.S. and K.D.,
respectively. Patient M.P. with a R152P (CGG→CCG) mutation
shows acampomelic CD. A P170R (CCG→CGG) mutation
affecting a highly conserved proline residue was detected in male
patient T.L. The de novo nature of the latter two mutations was
inferred from their absence in parental DNA.
A de novo deletion of 10 bp [nucleotide (nt) position
1192–1201; numbering according to ref. 3], resulting in a codon
encoding a mutant serine residue at aa position 277 followed by
an opal stop codon, was detected in the SOX9 gene of patient
L-M.A.. Another 43 bp deletion (nt position 1442–1484) results
in a frameshift creating 11 mutant aa residues following residue
356 in patient F.
Table 1. SOX9 mutations in patients with campomelic dysplasia identified in this study
Patient Karyotype and Nucleotide (nt) position Amino acid position Survival time
gender and mutation and type of mutation
M.R. 46, XX, F nt 629, TGG→TAG W86X, nonsense, de novo 12 days
A.S. 46, XY, F nt 695, CCC→CTC P108L, missense 6 months
J.N. 46, XY, F nt 721, CAG→TAG Q117X, nonsense, de novo alive at 12 years
K.D. 46, XY, F nt 799, TGG→CGG W143R, missense 5 months
M.P. 46, XX, F nt 827, CGG→CCG R152P, missense, de novo 2 days
T.L. 46, XY, inv(9), M nt 881, CCG→CGG P170R, missense, de novo 1 month
L–M.A. 46, XX, F del(1192–1201) frameshift at codon 277 10 weeks
F 46, XY, F del(1442–1484) frameshift at codon 357 2 days
M.J. 46, XY, F nt 1495, CAG→TAG Q375X, nonsense, de novo 7 weeks
P.G. 46, XY, M nt 1570, GAG→TAG E400X, nonsense 10 weeks
N.Z. 46, XX, F nt 1692, TAC→TAG Y440X, nonsense alive at 11 years
R.R. 46, XY, M no mutation found no mutation found alive at 5 years
Numbering of nucleotide and amino acid positions are according to ref. (3). For the position of the mutations relative to the SOX9 gene structure, see Figure 3. F,
female; M, male.
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A nonsense mutation within codon 375 (Q375X, CAG→TAG)
is localized in the distal part of the PQA-encoding region of
patient M.J., leaving 36 of 41 amino acid residues of this domain
intact. Both parents are homozygous for the wild-type allele,
proving that the Q375X mutation is de novo. A further nonsense
mutation at codon 400 (E400X; GAG→TAG) results in skeletal
malformations, but not in XY sex reversal in patient P.G. In this
case, the HMG domain remains intact, whereas the transactiva-
tion domain at the C-terminus of the protein is missing.
Previously, we reported a de novo nonsense mutation within
codon 440 (Y440X; TAC→TAG) in patient S.P. (3). We have now
identified the same Y440X mutation in another patient, N.Z. This
stop codon mutation results in a truncated protein missing 70 aa
residues at its C-terminus. S.P., a sex reversed XY female, survived
for 4 years (13), whereas N.Z., a karyotypic and phenotypic
female, is still alive at the age of 10. Maternal, but not paternal
DNA, could be tested and proved negative for the mutation.
Finally, in CD patient R.R., as in patients H.H. and J.M.
analysed previously (3), no mutation could be detected by
sequencing of the open reading frame (ORF) and promoter region
(from start codon to nt –133) of SOX9. To see whether or not one
of the SOX9 alleles may have been deleted, a Southern blot
prepared from EcoRI-digested genomic DNA of all of the three
CD cases was hybridized simultaneously with the SOX9 cDNA
probe 4.1 (3) detecting a 6 kb EcoRI fragment, and with cDNA
probe pUCTAT2.16 from the human tyrosine aminotransferase
(TAT) gene (14) detecting a 5.8 kb EcoRI fragment from
chromosome 16. The signal intensity of the SOX9-specific
fragment relative to the TAT control fragment was the same in the
CD cases and in controls (not shown), indicating that both SOX9
alleles are present. Patients R.R. and J.M. are heterozygous for the
G/C polymorphism at nt 879 (3). This observation also confirms
presence of both alleles.
Mutant SOX9 proteins with reduced and abolished
transactivation activity
As mentioned above, patients S.P. (3) and N.Z. (Table 1) share the
recurrent stop codon mutation Y440X that truncates the C-terminal
transactivation (TA) domain spanning residues 402–509 (11).
Both patients survived the neonatal period by years. In contrast,
patient GM04329 (5) with a frameshift at codon 507 leaving all
of SOX9 including the TA domain essentially intact, but
extending the protein by 70 mutant residues, died shortly after
birth. We have elucidated the mutation in the SOX9 gene of this
patient, a girl with karyotype 46, XX, as a duplication of the
ACTC motif at nt position 1891. In order to understand the cause
for the differences in the state of health of the patients, we grafted
residues 402–439 of the TA domain of SOX9 to the DNA binding
domain of yeast transcription factor GAL4 (Fig. 1a) and
measured transcriptional activation of a GAL4-dependent CAT
reporter plasmid cotransfected in COS-7 cells, as previously
described (11). As shown in Figure 1b, the resulting fusion
protein GAL4-SOX9/402–439 shows threefold CAT-induction,
whereas the full length SOX9 grafted to the GAL4 domain
(GAL4-SOX9/1–509) gives 12-fold CAT-induction compared
with the value obtained for the GAL4 domain alone. These data
identify a residual transcription activation potential for residues
402–439 of SOX9. These residues are still present in the
mutationally truncated proteins from patients S.P. and N.Z. As
also shown in Figure 1, grafting of the mutationally extended
SOX9 protein of patient GM04329 to the GAL4 domain results in
fusion protein GAL4-SOX9/1–577, which shows no increase in
CAT-induction. To check for correct protein size and stability of the
GAL4 fusion proteins, Western blot analysis was performed using
a GAL4-specific polyclonal antibody. As illustrated in Figure 1c,
GAL4-SOX9/1–509 and GAL4-SOX9/402–439 show correct size
and stability as does the GAL4 domain alone. By contrast, fusion
protein GAL4-SOX9/1–577 shows correct size but strongly reduced
amounts of protein. This result was obtained for nuclear extracts
from independent transfection experiments. It appears that the
extension of SOX9 by 70 residues creates an unstable mRNA or
protein, thus explaining the lack of transactivation observed in
Figure 1b.
Amino acid substitutions in the HMG domain of SOX9
lead to reduced or abolished DNA binding
The point mutations causing the aa substitutions P108L, W143R,
R152P and P170R found in four CD patients (see above) were
introduced by site-directed mutagenesis into plasmid
pCDNA3-SOX9-HMG (see Materials and Methods) containing
the wild-type SOX9 HMG box. Proteins were expressed from the
wild-type and mutant constructs using a coupled in vitro
transcription/translation system. They were subsequently tested
in a gel retardation assay to see whether the mutant SOX9 HMG
domains show altered DNA binding abilities. The wild-type
SOX9 HMG domain readily binds oligonucleotide A containing
the high-affinity binding site AACAAT for murine (15) and
human SRY (16) (Fig. 2, lane 3), but not the control oligo-
nucleotide C (Fig. 2, lane 2) with a mutant binding sequence. Of
the four mutant SOX9 HMG-domains, P108L and W143R
completely fail to bind oligonucleotide A (Fig. 2, lanes 5 and 6),
while R152P and P170R show reduced DNA binding, forming
complexes that reproducibly move faster (Fig. 2, lane 4) or slower
(Fig. 2, lane 7) than the complexes formed by the wild-type HMG
domain. In these experiments, an unspecific complex is formed
by proteins present in the wheat germ extract (Fig. 2, lane 1).
Absence of SOX9 mutations in sex reversed patients
with XY gonadal dysgenesis
To find out whether mutations in SOX9 may also result in XY
gonadal dysgenesis (Swyer syndrome), as do mutations in the
related testis determining gene SRY, we examined 91% of the
SOX9 ORF and the four exon/intron boundaries in a total of 18
patients with Swyer syndrome by SSCP analysis. All cases have
proved negative for mutations in the SRY ORF in SSCP assays
and by DNA sequencing (17,18, and unpublished data). In none
of the cases could an altered SOX9 banding pattern be detected
(data not shown), providing evidence that SOX9 mutations do not
usually result in XY sex reversal without skeletal malformations.
DISCUSSION
Here we present 10 novel mutations and one recurrent mutation
in SOX9, the gene responsible for both CD and autosomal XY sex
reversal. Including 13 SOX9 mutations previously reported (3–5),
altogether 24 SOX9 mutations are now known (see Fig. 3). Nine
of them are located within the HMG box, which encodes the DNA
binding domain of the protein. These nine mutations include all
six amino acid substitutions described so far in CD. As the amino
acid sequences of SOX9 proteins from human (3,4), mouse (8)
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Figure 1. Effects of nonsense mutation Y440X and of frameshift mutation
(+ACTC) at codon 507 on the transactivation function of SOX9. (a) Constructs
used. 1, DNA-binding domain of yeast GAL4 (amino acids 1–147, given as
filled bar). 2, wild-type SOX9 fused to GAL4. 3, part of the TA domain retained
in Y440X mutated SOX9 fused to GAL4. 4, mutant SOX9 with C-terminal
extension due to (ACTC)-duplication at codon 507 and resulting frameshift
fused to GAL4. HMG, high mobility group domain; TA, transactivation
domain. (b) Results of CAT assays. Constructs 1–4 shown in (a) were
co-transfected with GAL4-dependent CAT reporter plasmid 17mertkCAT (29)
into COS-7 cells and were tested for stimulation of CAT activity. CAT values
obtained for each construct are given relative to the value obtained for GAL4
alone, set at 1. Values were averaged from three independent experiments, with
standard deviations below 20%. (c) Western blot. Nuclear proteins from
untransfected 293 cells (mock) or from 293 cells transfected with constructs
1–4 shown in (a) were detected by a GAL4-specific antibody following Western
blotting. Proteins of the expected size are visible in lanes 1–4 and are marked
by asterisks. Note the reduced amount of fusion protein in lane 4, compared
with lanes 1–3 showing higher and roughly equal amounts of protein. Position
of size markers (Rainbow marker, Amersham) are given at left.
and chicken (GenBank accession no. U12533) are highly
conserved over the entire N-terminal half of the protein, including
the HMG domain, and within the C-terminal TA domain (11), it
appears that the amino acid sequence of the HMG domain is
particularly critical for correct function.
All four patients carrying the missense mutations P108L,
W143R, R152P and P170R died within 6 months after birth. We
have analysed these mutations with respect to their effects on
DNA binding of the resulting mutant HMG domains. The P108L
Figure 2. Amino acid substitutions in the HMG domain of SOX9 reduce or
abolish DNA binding. Gel retardation assays were performed with equal
amounts of protein obtained from a coupled wheat germ in vitro transcription/
translation reaction, together with oligonucleotide probes A (oligo A) or C
(oligo C) containing the target sequence AACAAT or the nontarget sequence
AACCCA, respectively (18). Lane 1, protein synthesis reaction without added
template, together with oligo A. Lanes 2–7, wild-type or mutant SOX9 HMG
domains, as indicated. Position of free and bound probe is indicated at right, as
is an unspecific complex formed by proteins in the wheat germ extract.
and W143R mutations cause complete loss of binding, while the
HMG domains with the R152P and P170R mutations show
reduced DNA binding (Fig. 2). The observation that the latter two
mutations result in protein/DNA complexes moving slower or
faster than the wild-type complexes may indicate that these amino
acid complexes also result in an altered DNA bending angle, as
has been demonstrated for one amino acid substitution in the
HMG domain of SRY found in an XY female with gonadal
dysgenesis (19). However, SOX9 has not yet been shown to be
a DNA binding protein.
The W143R mutation affects the most conserved amino acid
residue among the HMG domain proteins. This residue is present
at a corresponding position in 39 of 44 members of this protein
family and is present in all SOX proteins (20). It is not surprising,
therefore, that the W143R mutation shows complete loss of DNA
binding. Interestingly, replacement of the corresponding tryptophan
residue by arginine in the HMG domain of the HMG1 protein
results in an altered protein structure and affects many, but not all,
of its DNA binding properties (21,22).
Of all SOX9 mutations that are not missense mutations, only the
recurrent nonsense mutation Y440X found in patients S.P. (3) and
N.Z. (Table 1) and the frameshift mutation at codon 507 in patient
GM04329 (5) leave part or almost all of the TA domain intact
(Fig. 3). We have demonstrated in functional transfection assays
that the truncated SOX9 protein resulting from the Y440X
mutation retains some transactivation function, while the mutant
SOX9 protein resulting from the codon 507 frameshift shows no
transactivation, probably due to instability of the protein, or its
mRNA (Fig. 1). These findings correlate with the clinical course
of the patients involved, as S.P. and N.Z. survived the neonatal
period, whereas patient GM04329 died shortly after birth. The
other nonsense and frameshift mutations described so far, and the
two splice mutations, result in SOX9 proteins that entirely lack
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Figure 3. Summary of presently known SOX9 mutations in campomelic dysplasia and autosomal XY sex reversal. Exons 1–3 of SOX9 are drawn to scale, with exon 3
being truncated. Coding sequences are indicated by gray, stippled (HMG domain), cross-hatched (PQA motif) or black boxes (transactivation domain), untranslated
regions by white boxes. Numbers indicate codons or amino acid residues, given as single letter code. The nature of the mutations is indicated at left. The number of
bases inserted or deleted in frameshift mutations is given in brackets. Mutations found in XY and XX females are marked by filled and open circles, respectively, while
mutations present in XY males are indicated by open squares. Data are from this report (Table 1); ref. 3 (E148X, Y440X, 329(+1), splice donor GT→AT); ref. 4 (Q195X,
261(+1), 286(+1); and ref. 5 (F112L, A119V, 368(+1), 368(+1), 507(+4), splice acceptor AG→CG).
the TA domain; additionally, some mutant SOX9 proteins lack
part or all of the HMG domain (Fig. 3). As might be expected,
most of the patients having such severely impaired SOX9
proteins died in the neonatal period. This is the case for most of
the patients previously described (3–5), and for five of the six
such patients with nonsense mutations W86X, Q375X and
E400X, and those with frameshift mutations at codons 277 and
357 (Table 1, see also patient reports). However, patient J.N.
carrying the nonsense mutation Q117X at the N-terminus of the
HMG domain is now doing well at the age of 12 years.
Four SOX9 mutations in phenotypic male CD patients have
now been reported. Two are amino acid substitutions in the HMG
domain, F112L (5) and P170R (Table 1) (see Fig. 3). Whereas the
F112L mutation has not been tested functionally, the P170R
mutation in patient T.L. has been shown to retain some DNA
binding ability (Fig. 2). While it is tempting to correlate this with
the lack of sex reversal seen in this patient, we are reluctant to do
so in view of the fact that residual DNA binding has also been
documented for some amino acid substitutions in the HMG
domain of SRY found in XY females with gonadal dysgenesis
(18,19,23,24). The E400X mutation in the male patient P.G.
described here results in a truncated protein completely lacking
the transactivating domain at its C-terminus (11). As nonsense
mutations flanking codon 400 on either side are found in
sex-reversed XY females (Q375X and Y440X; Table 1), no
correlation between the position of a stop codon in SOX9 and the
sexual phenotype is apparent. Finally, a SOX9 mutation described
in a male CD patient is a single A insertion in codon 368 (5), but
an identical mutation was also found in a sex reversed XY female
(5) (Fig. 3), providing a particularly clear example that XY sex
reversal in SOX9 is subject to variable penetrance. None of the
four phenotypic and karyotypic male patients with known SOX9
mutations survived beyond the neonatal period. However, a case
of a 17 year old male long-term-survivor is documented (1,25).
Although cases of CD without male to female sex reversal are
common, no case of sex reversal without skeletal malformations
caused by a SOX9 mutation has been reported to date. As both
SRY and SOX9 act within the sex determination/differentation
pathway, one could assume that SOX9 mutations may also cause
gonadal dysgenesis and XY sex reversal (Swyer syndrome), as do
mutations in SRY. However, we detected no SOX9 mutations in 18
patients with Swyer syndrome carrying an intact SRY gene. As
only 91% of the gene has been analysed by SSCP in these 18
cases, we cannot completely rule out that SOX9 mutations may
occasionally cause Swyer syndrome in other patients.
In patient R.R. (Table 1), as in three patients previously studied
(3,5), no SOX9 mutations and no chromosomal rearrangements
could be detected. In all CD cases with chromosomal aberrations
analysed so far, the translocation breakpoints are located at
remarkable distances of 50 kb to more than 130 kb 5′ from SOX9,
providing evidence for an extended control region of the SOX9
gene (3,4,6,7). In the four CD cases with no detectable SOX9
structural gene mutation, the mutations may be located within the
putative far upstream regulatory element(s) affected by the
translocations. Alternatively, the mutations may reside within
intronic sequences of the SOX9 gene, or may affect the putative
expressed sequence 5′ to SOX9 described by Ninomiya et al. (26).
As discussed above, a major conclusion from this and from
previous reports is the lack of correlation between the type and
position of mutation within the gene with the resulting phenotype.
It appears that both XY sex reversal and disease severity are a
matter of penetrance of a mutation rather than the result of a
specific type of mutation: a patient may have a nonsense mutation
removing 80% of the protein and survive for several years, as in
patient J.N. with the Q117X mutation, while nonsense or
frameshift mutations leaving a much larger segment of SOX9
intact are found in patients who died in the neonatal period. The
only tentative genotype/phenotype correlation we can formulate
concerns the Y440X mutation, where the retention of some
transactivation potential may be causally related with the fact that
the two unrelated patients carrying this mutation survived for
several years. Future mutational studies of SOX9 in CD patients
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may show whether this correlation linking residual trans-
activating activity of a mutant SOX9 protein to an increased
survival rate will hold.
MATERIALS AND METHODS
Patient reports
M.R. (Vienna) is the third child of non-consanguineous, healthy
parents. One of her two sisters also suffered from CD and died
shortly after birth. M.R. showed severe hypoplasia of the scapulae,
bowing and shortening of femora and tibiae, clubfeet and low-set
ears. She died after 12 days from respiratory insufficiency. Autopsy
revealed symmetric hypoplasia of olfactory tracts and bulbs.
Karyotype was 46, XX.
Patient A.S. (Munich) is the third child of non-consanguineous
parents. She showed postnatal dyspnoea. Morphologic examin-
ation revealed flat face, low-set ears, cleft palate, shortened arms,
bowing of femora and tibiae, clubfeet, hypoplastic scapulae,
stenosis of the trachea and external female genitalia. She died 6
months after birth. Karyotype was 46, XY.
Patient J.N. (Loverval): Clinical details have been reported by
Gillerot et al. (referred as ‘patient 2’) (27). The external genitalia are
those of a normal female. Owing to her orthopedic problems, she is
now wheelchair bound. For her hypoacousia—characteristic of the
syndrome—she received an external amplifier and markedly
progressed in her psychomotor development. She is mildly
retarded, has a high-pitched voice and is now doing well with
good social capabilities. Her weight is 17.5 kg and her height is
of 102 cm (–6 SD) at the age of 12 years. Karyotype is 46, XY.
Patient K.D. (Leuven): First child of unrelated, healthy parents.
Presented with a large head, low-set ears, broad nasal bridge,
broad alveolar ridges, bifid uvula, bowed lower limbs with
pretibial skin ‘dimples’, and bilateral clubfeet. There was
hypoplasia of cervical (C5–C7) and dorsal (D1 and D2) vertebrae,
hypoplastic scapulae, diaphyseal angulation of femora, tibiae and
fibulae and short metacarpals in the fourth and fifth fingers. At 5
months the patient died of an apneic attack. Female type gonads
were reduced to fibrous streaks. Karyotype was 46, XY.
Patient M.P. (Aarhus): This case of a patient with acampomelic
CD has been published by Friedrich et al. (28). She died 2 days
after birth. Karyotype was 46, XX.
Patient T.L. (Suhl): Second child of nonconsanguineous
parents. His mother has bilateral hip dysplasia, his brother had
several hip operations. T.L. showed classical signs of CD
including Robin sequence, low-set ears, bowing of tibiae,
hypoplastic scapulae and bowed lower limbs. External genitalia
were of normal male type. The neonate died 4 weeks after birth.
Karyotype was 46, XY, inv(9) (p11q12).
Patient L-M.A. (Berlin) was the first child of healthy, unrelated
parents. She showed typical signs of CD: bowing of lower limbs,
clubfeet, hypoplasia of scapulae and fibulae, cleft palate,
hypoplasia of mandibula and tracheal/bronchial instability. She
died at 10 weeks of age. Karyotype was 46, XX.
Patient F. This case of a sex-reversed female has been published
by Ebensperger et al. (13). Karyotype was 46, XY.
Patient M.J. (Erlangen) was the first child of healthy, unrelated
parents. Her CD included short neck, hypoplastic mandible, a
large anterior fontanel, flat facies, low-set dysplastic ears, cleft
palate, bowed and shortened arms and legs, praetibial skin
‘dimples’ and normal female external genitalia. Radiography
showed hypoplasia of the cervical spine, the scapulae and the
pelvis, bowing of femora and tibiae, hypoplastic fibulae and short
metacarpal bones. Pyelography revealed low positioned kidneys
and mild dilatation of calices. She died after 7 weeks from
respiratory distress. Karyotype was 46, XY.
Patient P.G. (Chemnitz) was the first child of healthy parents.
Disproportionate short stature, macrocephaly and malformation
of the lower limbs were recognized by ultrasound examination
during early pregnancy. Postnatal examination confirmed ma-
crocephaly with prominent occiput, Robin sequence with cleft
palate and micrognathia, dislocation of the hips, normal male
external genitalia, short anteriorly bowed legs and talipes
equinovarus. Radiographic signs were narrow vertebral bodies,
11 pairs of ribs, hypoplasia of the scapulae and pelvic bones,
shortened upper limbs, antecurvation and varus deformity of the
femora and hypoplastic fibulae. He died after 10 weeks due to
respiratory distress. Karyotype was 46, XY.
Patient N.Z. (Zürich) was born as first child of healthy parents.
At 28 weeks of pregnancy, ultrasound indicated fetal growth
retardation. There was bowing of the femora, a very small
mandible, prominent forehead and prominent lower occiput,
small ears, narrow external ear canals, Robin sequence, bilateral
clubfeet, short limbs, especially rhizomelic brachymelia. Feeding
was through tube for the first 7 months. During the first 2 years
of life, she suffered from recurrent otitis. At 2 years a conductive
hearing loss was found bilaterally, more severe on the left. At the
age of 8 years, she had severe kyphoscoliosis with gibbus, pedes
adducti, impaired hearing and distinct developmental and mental
delay. She was placed in a remedial school. First steps without
support at 18 months, first words at 2 years. She is now 11 years
of age. Karyotype is 46, XX.
Patient GM04329 (see section ‘Mutant SOX9 proteins with
reduced and abolished transactivation activity’): This case of a
female with karyotype 46, XX has also been studied by
Kwok et al. (5). The patient died shortly after birth. Fibroblasts
were obtained from the Coriell Institute, Camden, USA.
Patient R.R. (Zurich): This mildly affected boy is still alive at the
age of 5 years. He shows hip dysplasia, micrognathia, mildly
bowed femora, humeri and radii, 11 pairs of ribs, macrocephaly,
and stenosis of the trachea. Scapulae were normal. He shows no
Robin sequence and no clubfeet. Karyotype is 46, XY.
PCR and sequence analysis
The three exons and the exon/intron boundaries of the SOX9 gene
were amplified by PCR using the primers and conditions
essentially as decribed (3). For the third exon, an additional
primer pair: E3-F4: 5′-CCC GGA GGG TGC CTA AGA CTA-3′,
E3-R1: 5′-GAT GTG CGT TCG CTG GGA CTG-3′, with a
resulting product of 583 bp, was used. DNA sequence analysis of
gel-purified PCR products was as described (3).
SSCP
Seven and a half µl PCR product and 7.5 µl denaturing solution
(95% formamide, 20 mM EDTA, 0.05% bromophenol blue,
0.05% xylene cyanol) were loaded on a 6% acrylamide/bisacryla-
mide (29:1) gel run in 45 mM Tris-borate buffer, pH 7.8, 1 mM
EDTA. If necessary, PCR products were digested by appropriate
restriction enzymes to yield fragment sizes below 300 bp.
Electrophoresis was carried out at 4C, 200 V for 15 h. Gels were
fixed for 20 min in 10% ethanol, 0.5% acetic acid and stained for
25 min in a 0.17% (w/v) silver nitrate solution. Stained gels were
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rinsed in water for 3 min and developed in 3% NaOH/0.1%
formaldehyde solution for 10–15 min. Development was stopped
by soaking the gel in fixation solution.
Constructs and CAT assays
Plasmids pABgal (29), designated as GAL4, and
GAL4-SOX9/1–509 were described (11). For constructing
GAL4-SOX9/1–577, a portion of the SOX9 gene derived from
patient GM04329 was amplified using primers E3-F-PII: 5′-GAC
GGA GCA GCT GAG CCC CAG-3′ spanning the PvuII site
(underlined) in the third exon of SOX9, and E3-R-BI: 5′-CAA
GCG TGG AG GAT CCT GGA GA-3′, introducing a BamHI site
(underlined) 319 nt 3′ from the wild-type stop codon and 119 nt
3′ from the stop codon of the mutant allele. The PvuII/BamHI
portion of GAL4-SOX9/1–509 was then replaced by the 647 bp
PvuII/BamHI-digested PCR product resulting in
GAL4-SOX9/1–577. In-frame insertion, presence of the ex-
pected mutation and lack of mutations created by Taq polymerase
was monitored by sequencing the resulting clones.
GAL4-SOX9/402–439 was constructed by amplifying a frag-
ment from the wild-type SOX9 gene using primers SOX9-TA2:
5′-GC GAC CCG GGG CTG AGC CCC AGC CAC TAC-3′ and
SOX9-C: 5′-GC GGA TCC CTA CTG TGA GCG GGT GAT
GG-3′; introduced BamHI and SmaI sites are underlined. The
resulting PCR product was cloned into the TA cloning vector
pCRII (Invitrogen), resulting in clone pCRII-SOX9/402–439,
and verified by sequencing. The 1.6 kb SmaI/BamHI fragment of
GAL4-SOX9/1–509 containing the whole SOX9 ORF was then
replaced by the 121 bp SmaI/BamHI fragment from pCRII-
SOX9/402–439 resulting in GAL4-SOX9/402–439.
Expression vector (0.25 pmol) was co-transfected into 1×106
COS-7 cells together with 1 pmol CAT reporter construct
17mertkCAT (29). CAT assay was essentially as described (30).
Constructs, mutagenesis and gel retardation assays
The HMG box of SOX9 was amplified by PCR from cDNA clone
4.1 (3). The 5′-primer, 5′-G CGG GAT CCG CCA GCC ATG
CAC GTC AAG CGG CCC ATG AAC-3′, contained a new start
codon (underlined) preceded by a Kozak sequence and followed
by 21 nucleotides from the 5′ end of the HMG box, and a BamHI
site for cloning. The 3′ primer, 5′-CCG GAA TTC TCT GCC
TCC GCC TGC CC-3′, spanned 18 nucleotides corresponding to
codons 185–190, followed by an EcoRI cloning site. Following
digestion with BamHI and EcoRI, the PCR product was inserted
in appropriately cut expression vector pcDNA3, resulting in
pcDNA3-SOX9-HMG, and verified by sequencing. An inframe
stop codon was provided by adjacent sequences of pcDNA3.
Mutations P108L, W143R, R152P and P170R (see Table 1) were
introduced into pcDNA3-SOX9-HMG using the QuikChange
site-directed mutagenesis kit (Stratagene). Proteins were ex-
pressed from the constructs using the TNT T7 coupled wheat
germ extract system (Promega) in the presence of 35S-methio-
nine. Correct size of proteins was determined by comparison with
the low range prestained SDS–PAGE standard (Bio-Rad). Equal
amounts of proteins (as determined by quantification of the
35S-methionine on a SDS–polyacrylamide gel) were used for gel
retardation analysis, together with 100 ng of oligonucleotide
probe A or C (18) 32P-labeled using T7 polynucleotide kinase.
Incubation of probe with protein, electrophoresis and autoradio-
graphy were essentially as described (18).
Western blotting
Approximately 105 human 293 cells, transfected by the calcium
phosphate method (31), were harvested after 36 h, lysed in
1×SDS buffer, and proteins were separated on a reducing 10%
SDS–polyacrylamide gel. Subsequently, proteins were trans-
ferred on to a PVDF-membrane (Biorad) in a semi-dry-blot
apparatus (Schleicher and Schüll). The detection of GAL4 fusion
proteins was performed by first washing the membrane twice in
TBST (10 mM Tris/HCl, pH 8, 150 mM NaCl, 0.05% Tween 20)
and a subsequent incubation in TBST containing 5% non-fat dry
milk powder for 1 h. The membrane was then incubated in a small
volume of TBST, containing an 1:500 dilution of an antibody
directed against the DNA-binding domain of the GAL4 protein.
After 4 h incubation at room temperature, the membrane was
washed eight times in TBST and incubated for another hour in
TBST containing a 1:3000 dilution of the anti-rabbit second
antibody coupled to horseradish peroxidase (Biorad). After
extensive washing the bound antibodies were detected using the
ECL-system (Amersham). Protein molecular weight was deter-
mined using the ‘rainbow marker’ (Amersham).
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ABBREVIATIONS
aa, amino acid(s); CAT, chloramphenicol acetyltransferase; CD,
campomelic dysplasia; HMG, high-mobility group (box, do-
main); nt, nucleotide(s); kb, kilobase pairs; ORF, open reading
frame; PCR, polymerase chain reaction; PQA, proline-gluta-
mine-alanine (motif); SSCP, single strand conformation poly-
morphism; TA, transcription activation (domain); TAT, tyrosine
aminotransferase.
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